Dr. Reddy’s Laboratories has launched Ertapenem for Injection, 1 g/vial, a generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial, which has approval from the US Food and Drug Administration (FDA) for the treatment of various bacterial infections.

The Indian pharma company has extended its partnership with Gland Pharma to launch Ertapenem for Injection in the US. INVANZ was developed by Merck.

Marc Kikuchi – CEO, North America Generics, Dr. Reddy’s Laboratories said: “We are pleased to bring this important product to market at this time.

“We’re excited to extend our strategic partnership with Gland Pharma whose hard work, in collaboration with the team at Dr. Reddy’s, has enabled the execution of this launch.”

The Indian pharma company said that its Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton.

As per IQVIA Health, the INVANZ brand and generic market had sales of around $205 million MAT in the US for the most recent 12 months that ended March 2021.

Srinivas Sadu – MD and CEO of Gland Pharma said: “We are delighted about this collaboration, as it brings together Dr. Reddy’s experienced marketing and distribution capabilities and Gland Pharma’s robust development and manufacturing capabilities.

“Gland Pharma has an exclusive API supply arrangement for this product and a dedicated manufacturing facility in Hyderabad for Ertapenem Injection. With the launch of this product we see increased capacity utilization of this dedicated Penem facility.”

  Bacterial Infections, Dr. Reddy’s Laboratories, Ertapenem for Injection, Hyderabad, India, INVANZ, Marc Kikuchi, Merck, Srinivas Sadu, USA